Euroopa Liit - hispaania - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - esclerosis múltiple - inmunosupresores selectivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Euroopa Liit - hispaania - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - inmunosupresores - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Ecuador - hispaania - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

centro de inmunologia molecular cuba - 5mg / ml - solucion inyectable - cada vial de 10 ml contiene nimotuzumab ???????????? 50,0 mg

Peruu - hispaania - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

roche farma (peru) s.a. - droguerÍa - trastuzumab emtansina - polvo para concentrado para solucion para perfusion - 160 mg - por vial - - trastuzumab emtansine

Hispaania - hispaania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

accord healthcare s.l.u. - mitoxantrona hidrocloruro - concentrado para soluciÓn para perfusiÓn - 2 mg/ml inyectable 10 ml - mitoxantrona hidrocloruro 2 mg - mitoxantrona

Hispaania - hispaania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

sandoz farmaceutica s.a. - mitoxantrona hidrocloruro - concentrado para soluciÓn para perfusiÓn - 2 mg/ml inyectable 10 ml - mitoxantrona hidrocloruro 2 mg - mitoxantrona

Hispaania - hispaania - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

mylan ire healthcare limited - mitoxantrona - concentrado para soluciÓn para perfusiÓn - 2 mg/ml inyectable 10 ml - mitoxantrona 2 mg - mitoxantrona

Peruu - hispaania - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

medifarma s.a. - concentrado para solucion para perfusion - por vial - mitoxantrona

Peruu - hispaania - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

global med farma s.a.c. - droguerÍa - concentrado para solucion para perfusion - por mililitro - - mitoxantrona

Euroopa Liit - hispaania - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod clorhidrato de - multiple sclerosis, relapsing-remitting; colitis, ulcerative - inmunosupresores - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.